Considering the FGFR aberration usually activates AKT-mTOR, PLCγ, and MEK-ERK pathways in cancer 1,2, we used the selective inhibitors or specific siRNAs to block these downstream signalings to test which could downregulate HK2. Here, MAP2K7 is linked to cancer.